Department of Psychiatry, University Hospital Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Seville, Spain.
Eur Psychiatry. 2022 Aug 16;65(1):e48. doi: 10.1192/j.eurpsy.2022.2308.
People with psychosis are at higher risk of cardiovascular events, partly explained by a higher predisposition to gain weight. This has been observed in studies on individuals with a first-episode psychosis (FEP) at short and long term (mainly up to 1 year) and transversally at longer term in people with chronic schizophrenia. However, there is scarcity of data regarding longer-term (above 3-year follow-up) weight progression in FEP from longitudinal studies. The aim of this study is to evaluate the longer-term (10 years) progression of weight changes and related metabolic disturbances in people with FEP.
Two hundred and nine people with FEP and 57 healthy participants (controls) were evaluated at study entry and prospectively at 10-year follow-up. Anthropometric, clinical, and sociodemographic data were collected.
People with FEP presented a significant and rapid increase in mean body weight during the first year of treatment, followed by less pronounced but sustained weight gain over the study period (Δ15.2 kg; SD 12.3 kg). This early increment in weight predicted longer-term changes, which were significantly greater than in healthy controls (Δ2.9 kg; SD 7.3 kg). Weight gain correlated with alterations in lipid and glycemic variables, leading to clinical repercussion such as increments in the rates of obesity and metabolic disturbances. Sex differences were observed, with women presenting higher increments in body mass index than men.
This study confirms that the first year after initiating antipsychotic treatment is the critical one for weight gain in psychosis. Besides, it provides evidence that weight gain keep progressing even in the longer term (10 years), causing relevant metabolic disturbances.
精神病患者发生心血管事件的风险较高,部分原因是体重增加的倾向性较高。这在首发精神病(FEP)患者的短期和长期(主要是 1 年)研究以及慢性精神分裂症患者的长期研究中都有观察到。然而,关于 FEP 患者在长期(3 年以上随访)体重进展的纵向研究数据较少。本研究旨在评估 FEP 患者在 10 年期间体重变化的长期(10 年)进展及其相关代谢紊乱。
对 209 名首发精神病患者和 57 名健康参与者(对照组)进行了评估,分别在研究开始时和 10 年随访时进行评估。收集了人体测量、临床和社会人口学数据。
首发精神病患者在治疗的第一年体重呈显著且快速增加,随后在研究期间体重增加幅度较小但持续(增加 15.2kg;SD 12.3kg)。体重的早期增加预示着长期变化,与健康对照组相比,体重增加更显著(增加 2.9kg;SD 7.3kg)。体重增加与血脂和血糖变量的改变相关,导致肥胖率和代谢紊乱的增加等临床后果。性别差异也有观察到,女性的体重指数增加幅度高于男性。
本研究证实,在开始使用抗精神病药物治疗后的第一年是精神病患者体重增加的关键时期。此外,它提供了证据表明体重增加甚至在长期(10 年)内仍在继续,导致相关的代谢紊乱。